PROJECT SUMMARY
Americans commonly consume excess amounts of dietary fructose. Added fructose has been shown to have an
adverse impact on metabolic health, including increased insulin resistance and type 2 diabetes (T2D) risk.
However, the mechanisms that link dietary fructose and metabolic health are poorly understood. Malabsorption
or incomplete metabolism of fructose in the small intestine is common in the population. Excess fructose reaches
the colon where it may change the structure and function of the gut microbiome, alter bacterial metabolites and
trigger inflammatory responses impacting T2D risk. To elucidate whether commonly consumed levels of dietary
fructose influence metabolic outcomes through altering the gut microbiome, we will randomize 30 participants to
a controlled cross-over dietary intervention, in which they will consume 12-day isocaloric, added fructose or
glucose diets (25% of total calories) separated by a 10 day controlled diet washout period. We aim to:
1: Determine the relationships between high fructose consumption, the gut microbiome and metabolic
risk.
2: Characterize the causal role(s) that fructose-induced alterations to the gut microbiome have on
metabolic risk using a germ-free mouse model.
We will measure 1) microbiota community structure and function via metagenomic sequencing of stool, 2) fecal
metabolites via targeted and untargeted metabolomics, 3) anthropometrics, 4) insulin resistance, serum markers
of T2D risk and inflammatory cytokines, 5) fecal microbial carbohydrate oxidation capacity and 6) liver fat via
MRI elastography. We will use novel statistical approaches, including Distributed Lag Modeling, to understand
the complex relationships between diet, the microbiome, metabolites and health outcomes.
We will then conduct controlled dietary interventions and fecal microbiome transplantation studies in germ-free
mice. Donor fecal samples from human participants in both the glucose and fructose arms of the clinical
intervention will be transplanted into germ-free and colonized mice to establish a causal relationship between
fructose-induced changes to the gut microbiome, liver fat and metabolic and inflammatory changes known to
increase risk for T2D.
We aim to comprehensively assess the structural and functional changes to the gut microbiome brought about
by a high fructose diet. Determining the impact of excess fructose on the microbiome will help identify novel
means by which fructose contributes to metabolic disease risk. In addition to identifying strategies to improve
metabolic health in adults, data from this proposal could help inform targeted approaches to mitigate future
disease risk in vulnerable populations that consume high levels of fructose, such as children.
